Sherbrooke Park Advisers LLC Xeris Biopharma Holdings, Inc. Transaction History
Sherbrooke Park Advisers LLC
- $230 Billion
- Q2 2025
A detailed history of Sherbrooke Park Advisers LLC transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Sherbrooke Park Advisers LLC holds 24,325 shares of XERS stock, worth $237,412. This represents 0.05% of its overall portfolio holdings.
Number of Shares
24,325
Previous 14,877
63.51%
Holding current value
$237,412
Previous $81.7 Million
39.09%
% of portfolio
0.05%
Previous 0.04%
Shares
3 transactions
Others Institutions Holding XERS
# of Institutions
214Shares Held
90.1MCall Options Held
81.6KPut Options Held
57.6K-
Black Rock Inc. New York, NY10.3MShares$101 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.82MShares$95.8 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY3.84MShares$37.4 Million0.01% of portfolio
-
State Street Corp Boston, MA3.78MShares$36.9 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.65MShares$35.6 Million0.0% of portfolio
About Xeris Biopharma Holdings, Inc.
- Ticker XERS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 135,956,992
- Market Cap $1.33B
- Description
- Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...